8-KEarnings & ResultsExhibits & Filings

AMGEN INC 8-K Report, Financial Results (Aug 4, 2026)

Filed August 4, 2026For Securities:AMGN

Summary

Amgen Inc. (AMGN) has filed an 8-K to report its second quarter 2026 financial results, primarily through the release of its earnings press release (Exhibit 99.1). The filing emphasizes the company's use of non-GAAP financial measures, including non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses, along with Free Cash Flow (FCF). Amgen utilizes these non-GAAP metrics to provide a more insightful view of ongoing business operations and to facilitate comparisons across periods, believing they enhance investor understanding of financial performance and future prospects. The press release details the specific items excluded from GAAP measures to arrive at these non-GAAP figures. These exclusions primarily consist of acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), costs associated with restructuring and cost-saving initiatives, and other non-recurring items like gains/losses on investments and legal settlements. The company asserts that these adjustments offer a more meaningful evaluation of current operating performance and comparability to historical results by treating internally developed and acquired assets similarly and excluding infrequent or non-operational events. Investors should review the full press release for detailed reconciliations and specific financial figures.

Key Highlights

  • 1Amgen Inc. filed an 8-K on August 4, 2026, announcing its unaudited results for the second quarter and first half of 2026.
  • 2The filing primarily references Amgen's earnings press release (Exhibit 99.1) for detailed financial performance.
  • 3The company heavily utilizes and explains its non-GAAP financial measures to provide a clearer view of ongoing operations.
  • 4Key non-GAAP metrics discussed include non-GAAP earnings per share, operating income, and operating margin.
  • 5Free Cash Flow (FCF) is also presented as a key liquidity measure, calculated as operating cash flow less capital expenditures.
  • 6Excluded items from GAAP to calculate non-GAAP measures include acquisition-related expenses, restructuring costs, and certain investment/legal gains/losses.
  • 7Amgen's management believes these non-GAAP measures enhance investor understanding by facilitating comparisons and focusing on core operational performance.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally report Amgen Inc.'s unaudited financial results for the second quarter and first half of 2026. It directs investors to the company's furnished earnings press release (Exhibit 99.1) for the specific financial details and performance commentary.

Amgen presents non-GAAP financial measures to provide investors with supplementary information that enhances their understanding of the company's ongoing business operations and future prospects. They believe these measures facilitate comparisons of results across different periods by excluding items that may be volatile or not indicative of core operational performance, such as acquisition-related expenses and restructuring costs.

Amgen excludes several categories of expenses from its non-GAAP financial measures. These include acquisition-related expenses (like amortization and impairment of acquired intangibles), costs associated with restructuring and cost-saving initiatives, and certain other items outside the ordinary course of business such as gains and losses on equity investments and legal proceedings. The company provides detailed reconciliations between GAAP and non-GAAP figures in its press release.

No, the information furnished in this Item 2.02 filing, including the earnings press release, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section. It is also generally not incorporated by reference into other SEC filings unless specifically stated.